Insulet | PODD - Ebitda


Insulet reported $199.8M in EBITDA for its fiscal quarter ending in June of 2026.





Ebitda Change Date
Abbott USD 2.43B 844M Mar/2026
Align Technology USD 229.14M 31.74M Mar/2026
AtriCure USD 27.28M 10.21M Jun/2026
Baxter International USD 309M 756M Mar/2026
Becton, Dickinson and Co. USD 1.71B 1B Jun/2026
Boston Scientific USD 1.63B 27M Jun/2026
Cardinal Health USD 955M 135M Jun/2026
Cooper Companies USD 67.9M 255.5M Mar/2026
Dexcom USD 364.5M 57.7M Mar/2026
Edwards Lifesciences USD 555.6M 485.5M Mar/2026
Eli Lilly USD 10.29B 1.86B Mar/2026
Globus Medical USD 279.84M 48.01M Jun/2026
ICU Medical USD 110.03M 11.35M Jun/2026
Insulet USD 199.8M 18.1M Jun/2026
Integra LifeSciences USD 78.41M 2.23M Jun/2026
J&J USD 8.27B 1.08B Mar/2026
Medtronic USD 2.63B 174M Jun/2026
Merit Medical Systems USD 104.39M 10.97M Jun/2026
Roche Holding CHF 13.43B 744M Jun/2026
Solventum Corp USD 670M 233M Jun/2026
Stryker USD 1.93B 357M Jun/2026
Tandem Diabetes Care USD 6.42M 3.69M Jun/2026
Teleflex USD 75.63M 171.44M Mar/2026
West Pharmaceutical Services USD 243.6M 17.4M Jun/2026
Zimmer Biomet Holdings USD 830.5M 190.4M Jun/2026